Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Ibrahim Nassour

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9845-1074; OpenAlex author ID A5036709127. Sources: OpenAlex.

Their work

Papers
27 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2020: 1 paper · 2021: 7 papers · 2022: 2 papers · 2023: 6 papers · 2024: 3 papers · 2025: 3 papers · 2026: 5 papers

Papers 27

  1. Neoadjuvant Radiation is Causally Linked to Increased Operative Time and Perioperative Blood Transfusion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.01.031↗
  2. Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. Co-author DOI 10.1093/oncolo/oyag250↗
  3. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18633-7↗
  4. Neoadjuvant Therapy for Localized Pancreatic Cancer. Last author DOI 10.3390/cancers18061011↗
  5. Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Last author DOI 10.3390/cancers18162642↗
  6. Implications of an Isolated Positive Vascular Groove After Whipple for Pancreatic Adenocarcinoma: A Single Institution, Retrospective Analysis. Co-author DOI 10.1002/jso.70052↗
  7. Oncologic Efficacy of Robotic Compared to Open Total Pancreatectomy for Pancreatic Cancer. Last author DOI 10.1016/j.jss.2024.10.043↗
  8. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Co-author DOI 10.1245/s10434-025-18842-0↗
  9. Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27595↗
  10. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27856↗
  11. Analysis of pancreatic cancer treatment and survival disparities in Florida throughout the Covid-19 pandemic. Co-author DOI 10.1016/j.jnma.2024.07.004↗
  12. Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05531-6↗
  13. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. First author DOI 10.1016/j.hpb.2022.12.002↗
  14. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.06.018↗
  15. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.06.007↗
  16. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon-2023-0256↗
  17. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15184464↗
  18. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  19. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. Co-author DOI 10.3389/fonc.2022.1086779↗
  20. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… Co-author DOI 10.1002/jso.26267↗
  21. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26510↗
  22. Medicaid expansion and the management of pancreatic cancer. Co-author DOI 10.1002/jso.26515↗
  23. Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s00464-020-07638-w↗
  24. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. First author DOI 10.1007/s11605-020-04870-6↗
  25. Perioperative and oncologic outcomes of open, laparoscopic, and robotic distal pancreatectomy for pancreatic adenocarcinoma. First author DOI 10.1007/s13304-020-00927-y↗
  26. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. First author DOI 10.1245/s10434-020-09446-x↗
  27. Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25958↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Paniccia · 19 shared papers, 2020–2026 · strength 3.52
  2. Amer H. Zureikat · 15 shared papers, 2020–2026 · strength 2.49
  3. Steven J. Hughes · 11 shared papers, 2022–2026 · strength 2.43
  4. Aatur Dilip Singhi · 7 shared papers, 2021–2026 · strength 1.32
  5. Jordan A. McKean · 4 shared papers, 2025–2026 · strength 1.14
  6. Thomas J. George · 5 shared papers, 2023–2026 · strength 1.11
  7. Kelly M. Herremans · 5 shared papers, 2022–2026 · strength 1.02
  8. Andrea N. Riner · 5 shared papers, 2022–2026 · strength 1.02
  9. Asmita Chopra · 5 shared papers, 2021–2026 · strength 0.95
  10. Patrick W. Underwood · 4 shared papers, 2023–2026 · strength 0.94
  11. Kathryn E. Hitchcock · 4 shared papers, 2023–2026 · strength 0.82
  12. Jesus C. Fabregas · 4 shared papers, 2023–2026 · strength 0.82
  13. Samer S. AlMasri · 5 shared papers, 2021–2024 · strength 0.81
  14. Sherise Chantell Rogers · 4 shared papers, 2023–2026 · strength 0.80
  15. Nathan Bahary · 5 shared papers, 2021–2023 · strength 0.68
  16. Richard S. Hoehn · 5 shared papers, 2020–2021 · strength 0.67
  17. Jose Gilberto Trevino · 3 shared papers, 2022–2026 · strength 0.64
  18. Hussein H. Khachfe · 3 shared papers, 2023–2024 · strength 0.56
  19. Abdul Qahar Khan Yasinzai · 2 shared papers, 2026 · strength 0.55
  20. Mohamed A. Adam · 4 shared papers, 2020–2021 · strength 0.54
  21. Samer T. Tohme · 4 shared papers, 2020–2021 · strength 0.53
  22. Siyang Zheng · 2 shared papers, 2025–2026 · strength 0.44
  23. Anwaar Saeed · 2 shared papers, 2025–2026 · strength 0.44
  24. Ryan Michael Thomas · 2 shared papers, 2023–2026 · strength 0.39
  25. Omar Roger Kayaleh · 2 shared papers, 2023–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.